Methods of predicting and monitoring tyrosine kinase...

Details Methods of predicting and monitoring tyrosine kinase... Methods of predicting and monitoring tyrosine kinase...

2011-03-15

2011-03-15

Zeman, Mary K (Department: 1631)

Data processing: measuring, calibrating, or testing

Measurement system in a specific environment

Biological or biochemical

C702S020000, C703S011000, C703S012000, C703S013000, C707S700000, C435S006120, C436S501000

Reexamination Certificate

active

07908091

ABSTRACT:
The present invention provides methods for analyzing a combination of biomarkers to individualize tyrosine kinase inhibitor therapy in patients who have been diagnosed with cancer. In particular, the assay methods of the present invention are useful for predicting, identifying, or monitoring the response of a tumor, tumor cell, or patient to treatment with a tyrosine kinase inhibitor using an algorithm based upon biomarker profiling. The assay methods of the present invention are also useful for predicting whether a patient has a risk of developing toxicity or resistance to treatment with a tyrosine kinase inhibitor. In addition, the assay methods of the present invention are useful for monitoring tyrosine kinase inhibitor therapy in a patient receiving the drug to evaluate whether the patient will develop resistance to the drug. Furthermore, the assay methods of the present invention are useful for optimizing the dose of a tyrosine kinase inhibitor in a patient receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects.

REFERENCES:
patent: 2005/0164196 (2005-07-01), Dressman et al.
patent: 2006/0115827 (2006-06-01), Lenz
patent: WO03/087404 (2003-10-01), None
patent: WO 2006/108627 (2006-10-01), None
Demetri et al., J. Clin. Oncol. ASCO Annual Meeting Proc., 23:4000 (2005)).
Kakiuchi et al.; Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839); Human Molecular Genetics; 2004; vol. 13, No. 24; pp. 3029-3043.
Moasser, The Tyrosine Kinase Inhibitor ZD1839 (“Iressa”) Inhibits HER2-driven Signaling and Suppresses the Growth of HER2-overexpressing Tumor Cells; Oct. 1, 2001; Cancer Research 61; pp. 7184-7188.
Okano, et al.; Proteomic Signature Corresponding to the Response to Gefitinib, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma; 2007; Clin Cancer Res.13(3): 799-805.
Cappuzzo, et al.; Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer; Journal of the National Cancer Institute; 2005; vol. 97, No. 9: 643-655.
Heinrich; Molecular basis for treatment of gastrointestinal stromal tumours; EJC Supplements; 2006; vol. 4, suppl. 1: 10-18.

Affiliated with

Also associated with

Rating

Methods of predicting and monitoring tyrosine kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of predicting and monitoring tyrosine kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of predicting and monitoring tyrosine kinase... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2683409